Evidence map›Paper›PMID 27480385›Full record

Trial reportLeukemia2017

Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial.

B Patel, A A Kirkwood, A Dey, D I Marks, A K McMillan, T F Menne, L Micklewright, P Patrick, S Purnell, C J Rowntree and 2 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01085617 (A Randomized Trial for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia), which is not on this map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
10.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01085617 completednot on this map

A Randomized Trial for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia

TypeinterventionalSponsorUniversity College, LondonRan2010 to 2025ConditionsLeukemia, Mucositis, Oral ComplicationsArmspalifermin, rituximab, cyclophosphamide, cytarabine, daunorubicin hydrochloride
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 116 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Article
  10. Asperginase-based chemotherapy regimen for acute lymphoblastic leukemia: A cohort study with promising outcomes on adults.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

B PatelBarts Cancer Institute, The London School of Medicine, Queen Mary University of London, London, UK.
A A KirkwoodCR UK and UCL Cancer Trials Centre, London, UK.
A DeyCancer Institute, University College London, London, UK.
D I MarksCentre for Clinical Haematology, Nottingham City Hospital, Nottingham, UK.
A K McMillanUnited Bristol Healthcare Trust, Bristol, UK.
T F MenneNewcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.
L MicklewrightCR UK and UCL Cancer Trials Centre, London, UK.
P PatrickCR UK and UCL Cancer Trials Centre, London, UK.
S PurnellCR UK and UCL Cancer Trials Centre, London, UK.
C J RowntreeCardiff and Vale UHB, London, UK.
P SmithCR UK and UCL Cancer Trials Centre, London, UK.
A K FieldingCancer Institute, University College London, London, UK.
University College London · GBCardiff and Vale University Health Board · GBNewcastle upon Tyne Hospitals NHS Foundation Trust · GBNorth Bristol NHS Trust · GBNottingham City Hospital · GBQueen Mary University of London · GB

Funding

Cancer Research UK 15953Cancer Research UK 9609Cancer Research UK A9609
6 · The paper itself

Abstract

Safety and efficacy data on pegylated asparaginase (PEG-ASP) in adult acute lymphoblastic leukaemia (ALL) induction regimens are limited. The UK National Cancer Research Institute UKALL14 trial NCT01085617 prospectively evaluated the tolerability of 1000 IU/m

Indexed as

AdultAgedAge FactorsAntineoplastic AgentsAsparaginaseChemical and Drug Induced Liver InjuryHumansInduction ChemotherapyMiddle AgedPhiladelphia ChromosomePolyethylene GlycolsPrecursor Cell Lymphoblastic Leukemia-LymphomaSepsisAntineoplastic AgentsAsparaginasepegaspargasePolyethylene Glycols

Identifiers

PMID27480385
PMCPMC5154375
OpenAlexW2485785171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.